Comment from National Drug & Alcohol Screening Association

Summary: The National Drug & Alcohol Screening Association (NDASA) supports the FDA's proposal to expand 510(k) exemptions for certain Class II medical devices to reduce regulatory burdens on the drug testing industry. They argue that workplace drug testing is a forensic public safety mission rather than a clinical diagnostic one and urge the FDA to further transition oversight to the National Laboratory Certification Program (NLCP).